Jpmorgan Chase & CO Pds Biotechnology Corp Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 619 shares of PDSB stock, worth $909. This represents 0.0% of its overall portfolio holdings.
Number of Shares
619
Previous 619
-0.0%
Holding current value
$909
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PDSB
# of Institutions
64Shares Held
4.06MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$2.24 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$715,8410.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$610,2160.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$344,2870.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA134KShares$197,3620.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $41.8M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...